Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP
{{output}}
Twenty percent of patients with high-tumor-burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Ritux... ...
